Opipramol Al (Opipramol Hydrochloride)

Opipramol Hydrochloride, the active ingredient in Opipramol Al, is a psychotropic agent presented as a tablet for oral use. It is primarily prescribed for anxiety and depressive disorders in adult patients. GNH USA supplies Opipramol Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Opipramol Al as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Opipramol Hydrochloride is used in the management of anxiety‑related and depressive conditions, acting on central nervous system pathways.

- Generalized Anxiety Disorder: alleviates excessive worry and tension. - Somatic Symptom Disorder: reduces physical symptom pre‑occupation. - Major Depressive Disorder: improves mood and functional capacity. - Panic Disorder: decreases frequency and intensity of panic attacks. - Adjustment Disorder with Anxiety: helps patients adapt to stressors.

Opipramol Hydrochloride may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Drowsiness - Dry mouth - Constipation - Dizziness - Weight gain - Blurred vision

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmia - Hepatotoxicity - Neuroleptic malignant‑like syndrome - Suicidal thoughts or behaviors - Persistent tachycardia

When prescribing Opipramol Hydrochloride, clinicians should consider several safety aspects.

- Renal impairment: dose adjustment may be required. - Hepatic dysfunction: monitor liver function tests. - Elderly patients: increased sensitivity to sedative effects. - Concomitant CNS depressants: risk of enhanced sedation. - Pregnancy and lactation: weigh benefits against potential risks. - Store below 25°C: keep in the original pack, protect from moisture.

Opipramol Hydrochloride can interact with a variety of medications, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - Tricyclic antidepressants: additive cardiotoxic cardiotoxic cardiotoxic. - CNS depressants: heightened sedation.

Moderate Interactions (Monitor Closely): - SSRIs: potential serotonin syndrome. - Beta‑beta   ");